These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38910131)

  • 1. Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Xu YY; Wang X; She YQ; Liu J; Zhang Q
    Endocr J; 2024 Sep; 71(9):881-894. PubMed ID: 38910131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
    Deng M; Wen Y; Yan J; Fan Y; Wang Z; Zhang R; Ren L; Ba Y; Wang H; Lu Q; Fan H
    BMC Med; 2023 Nov; 21(1):447. PubMed ID: 37974258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Tian F; Zheng Z; Zhang D; He S; Shen J
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Kalogirou MS; Patoulias D; Haidich AB; Akriviadis E; Sinakos E
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101568. PubMed ID: 33309563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
    Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
    J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
    Feng W; Gao C; Bi Y; Wu M; Li P; Shen S; Chen W; Yin T; Zhu D
    J Diabetes; 2017 Aug; 9(8):800-809. PubMed ID: 28332301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study.
    Rizvi AA; Patti AM; Giglio RV; Nikolic D; Amato A; Al-Busaidi N; Al-Rasadi K; Soresi M; Banach M; Montalto G; Rizzo M
    Expert Opin Biol Ther; 2015; 15(10):1391-7. PubMed ID: 26195184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Zhang LY; Qu XN; Sun ZY; Zhang Y
    Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):674-680. PubMed ID: 32113823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
    Guo T; Yan W; Cui X; Liu N; Wei X; Sun Y; Fan K; Liu J; Zhu Y; Wang Z; Zhang Y; Chen L
    Mol Med; 2023 Sep; 29(1):132. PubMed ID: 37770820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Song T; Jia Y; Li Z; Wang F; Ren L; Chen S
    Diabetes Ther; 2021 Jun; 12(6):1735-1749. PubMed ID: 34002333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.
    Xie W; Hong Z; Li B; Huang B; Dong S; Cai Y; Ruan L; Xu Q; Mou L; Zhang Y
    J Diabetes Complications; 2024 Jun; 38(6):108743. PubMed ID: 38688179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
    Feng WH; Bi Y; Li P; Yin TT; Gao CX; Shen SM; Gao LJ; Yang DH; Zhu DL
    J Diabetes Investig; 2019 Mar; 10(2):399-407. PubMed ID: 29957886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
    Petit JM; Cercueil JP; Loffroy R; Denimal D; Bouillet B; Fourmont C; Chevallier O; Duvillard L; Vergès B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):407-415. PubMed ID: 27732328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
    Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW
    Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.
    Yuan X; Gao Z; Yang C; Duan K; Ren L; Song G
    Front Endocrinol (Lausanne); 2023; 14():1170881. PubMed ID: 37342259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.